sluggish start eye spark
result mix second consecut quarter
driven guidanc modestli light
expect margin could prove conserv stage
set improv visibl keep us equal-
anoth mix quarter earli gate envista report revenu
miss estim second consecut
quarter organ core growth vs mse stabl
momentum basi revenu organ miss estim
driven continu headwind valu implant ration
commerci organiz chang estim
headwind despit premium segment growth flat manag
maintain view competit pressur underli caus
revenu organ estim see
continu near-term declin like given equip weak western
europ margin bp estim driven
product initi moder spend ep in-lin
estim revenu miss vs mse larg off-set lower opex
vs mse trend soften year trough
potenti growth recoveri prove deeper remain cautious optimist
tailwind name spark visibl specif end market pressur
top-line guidanc review envista guid core growth low-singl
digit larg line model preview see
compon guidanc follow growth lsd/msd flat
growth discontinu product impact bp note core
growth includ addit sell day bp
off-set net-neutr year despit sell day tailwind
manag commentari suggest growth cadenc build throughout
year valu implant ration initi anniversari new
product launch contribut primarili spark discuss model core
growth ex sell day assum neg
impact coronaviru china region may pose risk
continu model organ core growth acceler
throughout year comp eas new product traction build discuss
 guidanc modestli light could prove conserv ep guidanc
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
consensu midpoint margin guidanc
bp y/i adjust public compani cost light
estim like prove conserv consist thesi despit
top-line miss envista beaten margin estim bp bp
respect mainli driven cost leverag see continu
aid favor mix implant growth recov new
product traction drive margin accret fx less sever headwind
model margin may prove conserv note bp
margin upsid drive ep consist top-line see ep
build throughout year consist histor season like
envista invest behind new product launch earlier year model
modestli guidanc see potenti upsid driven
spark key catalyst acceler manag reiter expect
new product drive bp growth major
spark math impli increment revenu
modestli initi assumpt see launch trajectori
understand initi roll-out began hand core ormco custom
consist prior commentari phased/control roll-out
manufactur capabl remain key focu ormco forum set mid-
februari expect spark signific focu key catalyst
broader orthodontist roll-out outsid us envista receiv regulatori
approv spark china expand expect
materi growth driver spark continu see spark
traction build throughout year model revenu bp
growth impli share may prove conserv note increment
spark upsid drive bp envista growth
lighter start look brighter equal-weight thesi base
uncertain outlook near-term larg play envista
post two mix quarter gate saw valuat
appropri price acceler thesi yet proven
said remain posit prospect primarili spark like
drive organ growth flat continu view margin estim
conserv beyond see key valu driver
share intermedi term mix cost improv program drive
least pt margin see price target base
ebitda turn discount
price target base base case ebitda
estim turn discount see
justifi given lower growth margin profil howev modestli
off-set envista maintain superior yield vs dentspli
spark uptak occur faster anticip growth acceler
onward result favor mix combin
cost initi drive bp margin annual impli mid-teen earn
growth forese futur price pressur less sever statu quo
envista anniversari channel disrupt segment
ration effort pressur implant growth segment return
market growth spark acceler growth
distributor realign ensu volatil channel new product uptak
mute competit pressur rise dso preval drive
materi price headwind pt per year growth remain
rang margin expans limit due price unfavor mix
envista lead manufactur dental
implant comprehens portfolio
equip consum
compani move past acut industri
disrupt past year
launch sever new product
drive revenu acceler
margin expans initi could
meaning driven improv product mix
cost save program
pt market share clear
align market drive pt organ growth
pt market share fully-tap
implant market drive bp organ
bp margin expans drive pt
reduct interest expens
share repurchas bp reduct tax
rate add pt ep growth
spark clear align launch us
risk achiev price
price pressur result dso
mute new product uptak implant
spark clear align
distributor realign result
million except ep
sale
sale
sale
sale
sale
sale
sale
sale
dollar million except per share data
dollar million except per share data
dollar million except per share data
equival
dollar million except per share data
restructur impair charg
chang work capit
oper activ
sale pp
invest activ
net transfer parentco
purchas non-controlling interest
proce debt issuanc
repay debt
proce equiti issuanc net
financ activ
effect exchang rate
